Our Platform

VBL is pioneering a new class of drugs called Lecinoxoids to treat immune-inflammatory conditions. Using its unique drug discovery capabilities, VBL Therapeutics has developed a series of proprietary phospholipid analogs from the Lecinoxoid family that are rationally designed as orally available anti-inflammatory medicines to address the substantial unmet needs in immune-inflammatory diseases, including psoriasis, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis and atherosclerosis.